Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Fiona Herr"'
Autor:
Yang Zhao, Jackson Tang, Huanxue Zhou, Fiona Herr, Takeshi Takehashi, Takanobu Nomura, Eslie Dennis, Oleg Akilov
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:HSR22-182
Autor:
Martine Bagot, Stéphane Dalle, Lubomir Sokol, Athansios Tsianakas, Amy Musiek, Pablo L. Ortiz‐Romero, Brian Poligone, Madeleine Duvic, Craig Elmets, Mollie Leoni, Karen Dwyer, Takahiro Ito, Fiona Herr, Youn H. Kim
Publikováno v:
Dermatologic therapy. 35(8)
Autor:
Julia Scarisbrick, Karen Dwyer, Martine Bagot, Pierluigi Porcu, Pier Luigi Zinzani, Youn H. Kim, Wei Sun, Steven M. Horwitz, Fiona Herr, Alison J. Moskowitz
Publikováno v:
Leukemialymphoma. 62(13)
Patients with mycosis fungoides (MF) and Sezary syndrome (SS) often require multiple lines of systemic therapy. In the phase 3 MAVORIC study (NCT01728805), mogamulizumab demonstrated superiority to vorinostat in median progression-free survival (PFS)
Autor:
Hélène Moins-Teisserenc, Fiona Herr, Martine Bagot, Adèle de Masson, Michael S. Khodadoust, Takahiro Ito, Youn H. Kim, Karen Dwyer
Publikováno v:
European Journal of Cancer. 156:S48-S49
Background The MAVORIC study, a phase 3, open-label, multi-center, randomized controlled trial, compared the safety and efficacy of mogamulizumab with vorinostat in patients with mycosis fungoides (MF) or Sézary syndrome (SS) that relapsed/was refra
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S415-S416
Context Cutaneous T-cell lymphomas (CTCLs) are rare non-Hodgkin lymphomas that present in skin and include mycosis fungoides (MF) and Sezary syndrome (SS) subsets. Leukemic involvement is an independent prognostic factor affecting overall and disease
Autor:
Larisa Geskin, Brigitte Dréno, Athanasios Tsianakas, Steven M. Horwitz, Richard A Cowan, Stacie Hudgens, Mollie Leoni, Lysbeth Floden, Marie Beylot-Barry, Stéphane Dalle, Stephen Dale, Madeleine Duvic, Pierluigi Porcu, Dolores Caballero, Alison J. Moskowitz, Pietro Quaglino, Auris Huen, Fiona Herr, Martine Bagot
Publikováno v:
Clin Lymphoma Myeloma Leuk
Sézary syndrome (SS) and mycosis fungoides (MF), 2 types of cutaneous T-cell lymphoma, cause significant morbidity and adversely affect patients' quality of life (QoL). The present study assessed the QoL measurement changes in patients receiving mog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aabd0a27f1d1b60bae4fc19a10ab671e
http://hdl.handle.net/2318/1815295
http://hdl.handle.net/2318/1815295
Poster: TCL-389: Health-Related Quality of Life Effect of Mogamulizumab by Patient Blood Involvement
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S249
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S248
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S412
Context Mogamulizumab is an anti-CCR4 antibody for patients with relapsed/refractory mycosis fungoides (MF) or Sezary syndrome (SS). The mechanism of action of mogamulizumab involves depletion of CCR4+ T cells and potential to induce lymphopenia. Obj
Autor:
Paul Haun, David C. Fisher, Karen Dwyer, Maarten H. Vermeer, Youn H. Kim, Steven M. Horowitz, Amy Musiek, Martine Bagot, Takahiro Ito, Fiona Herr, Auris Huen, Sean Whittaker
Publikováno v:
Blood. 136:23-24
Background MAVORIC was a phase 3, open-label, multi-center, randomized controlled trial that evaluated the safety and efficacy of mogamulizumab compared with vorinostat in patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (